Welcome!

News Feed Item

US Excipients Market



 

 

 

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:



US Excipients Market

http://www.reportbuyer.com/pharma_healthcare/general_industry/us_excipients_market.html


US demand to grow 4.3% annually through 2018

Demand for pharmaceutical excipients in the US is projected to rise 4.3 percent per year to $2.0 billion in 2018. In volume terms, demand is expected to grow 1.9 percent annually to 900 million pounds over the same period. While continued growth in pharmaceutical output will be the primary driver of increases in excipient demand, gains will accelerate as excipients play a larger role in bringing additional value to pharmaceutical products by improving properties such as the controlled release or improved
absorption of active ingredients.


Preservatives, suspension agents to see strong gains

Trends in pharmaceutical output by dosage formulation will have a strong influence on excipient demand by application. Output of parenteral preparations is expected to rise at an especially strong pace through 2018, supporting demand for suspension agents and preservatives. Solvents are also projected to benefit from increased shipments of parenteral drugs, although gains in dollar terms will be limited by the continued decline in glycerin prices due to oversupply.
Oral preparations are the largest category of pharmaceutical dosage formulations; thus, oral pharmaceuticals tend to require more excipients than other types of drugs and have a significant impact on excipient demand. Shipments of oral pharmaceuticals are forecast to rise at a faster pace than seen in the 2008-2013 period, supporting accelerated gains in demand for fillers, binders, coatings, flavoring agents, capsules, and disintegrants. In addition, oral formulations such as delayed- and extended-release tablets and capsules and dissolving tablets are expected to boost their market share, further raising demand for excipients such as binders and disintegrants.


Specialty excipient blends to add value to product mix

A major development in the excipient and pharmaceutical industries is the increased dependence on specialty excipient blends. Specialty excipient blends can add value to pharmaceutical products by differentiating them from competitive products, and by optimizing the production process. These value-added excipient blends are often formulated for usage in specific manufacturing processes such as direct compression or wet granulation, and are optimized for certain performance characteristics such as delayed- or extended-release oral tablets. Product differentiation will play an increasingly important role going forward as generic pharmaceutical products increase their market share and as consumers take a more active role in choosing their drugs from among a wide range of products with the same active pharmaceutical ingredients.


Polymers to benefit from specialty blend advances

Product versatility will be a key factor impacting product mix in excipient demand going forward, especially as specialty excipient blends play an increasingly important role in pharmaceutical formulation. Polymers -- including cellulose derivatives, povidone, starch, polyethylene glycol, acrylic polymers, and natural gums -- are expected to benefit from this trend as many of these products can function in multiple applications and are easily formulated with other excipients. These favorable characteristics will serve to offset the higher prices associated with some polymers.


Study coverage

Excipients, an upcoming industry study presents historical demand data (2003, 2008, 013) plus forecasts for 2018 and 2023 by product type and application. This study also analyzes market environment factors, evaluates company market share and profiles 47 US industry competitors.
INTRODUCTION x
I. EXECUTIVE SUMMARY 1
II. MARKET ENVIRONMENT 4
General 4
Economic Factors 5
Demographic Patterns 9
Health Care Trends 13
National Health Expenditures 14
Medical Conditions 17
Chronic Conditions 18
Acute Conditions 20
Pharmaceuticals 22
Therapeutic Class 23
Dosage Formulations 24
Distribution Classifications 26
Commercial Status 28
Regulatory Overview 29
Historical Market Trends 31
Pricing Trends 32
Foreign Trade 34
International Markets 35
III. PRODUCTS 37
General 37
Polymers 43
Cellulose Derivatives 46
Microcrystalline Cellulose (MCC) 47
Hydroxypropyl Methylcellulose (HPMC) 50
Ethyl Cellulose 54
Methyl Cellulose 55
Carboxymethylcellulose (CMC) 57
Croscarmellose Sodium 59
Other Cellulose Excipients 61
Povidone 64
Starch Compounds 67
Pregelatinized Starch 69
Sodium Starch Glycolate 71
Other Starch Excipients 73
Polyethylene Glycol 77
Acrylic Polymers 80
Other Polymers 84
Natural Gums from Seaweeds 85
Other Natural Gums 88
All Other Polymers 90
Alcohols 91
Propylene Glycol 93
Glycerin 94
Sorbitol 96
Other Alcohols 98
Mannitol 99
Other Polyol Excipients 100
All Other Alcohols 104
Minerals 104
Calcium Phosphate 107
Calcium Carbonate 109
Clay 110
Mineral Hydrocarbons 112
Silicon Dioxide 115
Titanium Dioxide 117
Other Minerals 118
Gelatin 121
Sugars 125
Lactose 127
Sucrose 129
Other Sugar Excipients 131
Other Pharmaceutical Excipients 134
Dyes & Pigments 137
Flavors 138
Surfactants 139
Acidulants 142
Antioxidants & Antimicrobials 143
All Other Compounds 145
Stearate Compounds 145
Electrolytes & Related Compounds 146
Chemical Plasticizers 146
High Intensity Sweeteners 147
Natural Fats & Oils 149
Natural Waxes 150
IV. APPLICATIONS 152
General 152
Fillers & Diluents 155
Binders 157
Suspension & Viscosity Agents 160
Coatings 162
Solvents 164
Flavoring Agents 166
Capsules 168
Disintegrants 171
Colorants 173
Lubricants & Glidants 174
Preservatives 176
Other Applications 177
V. INDUSTRY STRUCTURE 179
General 179
Market Share 181
Competitive Strategies 184
Industry Restructuring 185
Cooperative Agreements 187
Marketing & Distribution 191
Research & Development 192
Manufacturing 193
Company Profiles 194
ABITEC, see Associated British Foods
Akzo Nobel NV 195
ANGUS Chemical, see Dow Chemical
Archer-Daniels-Midland Company 196
Ashland Incorporated 198
Associated British Foods plc 201
Avantor Performance Materials Incorporated 204
BASF SE 206
Berkshire Hathaway Incorporated 209
Berwind Corporation 211
Cabot Corporation 213
Cargill Incorporated 215
Celanese Corporation 218
Colorcon, see Berwind
Corn Products International, see Ingredion
CP Kelco US, see Huber (JM)
Croda International plc 220
CyDex Pharmaceuticals, see Ligand Pharmaceuticals
Dow Chemical Company 222
DuPont (EI) de Nemours 227
Eastman Chemical Company 229
EMD Millipore, see Merck
Evonik Industries AG 231
Ferro Corporation 234
FibroGen Incorporated 235
FLAVORx Incorporated 236
FMC Corporation 237
GELITA AG 239
Generichem Corporation 240
Huber (JM) Corporation 241
Huntsman Corporation 244
Ingredion Incorporated 245
Innophos Holdings Incorporated 247
JRS Pharma, see Rettenmaier (J.) & Söhne
Kraft Foods Group Incorporated 248
Kuraray Company Limited 249
Ligand Pharmaceuticals Incorporated 250
Lubrizol, see Berkshire Hathaway
LyondellBasell Industries NV 252
Merck KGaA 253
Mutchler Incorporated 255
Nitta Gelatin Incorporated 256
NutraSweet Company 257
Nutrinova, see Celanese
P&G Chemicals, see Procter & Gamble
PB Gelatins, see Tessenderlo Group
Pfanstiehl Incorporated 258
Procter & Gamble Company 259
Rettenmaier (J.) & Söhne GmbH & Company KG 260
Roquette Frères SA 262
Royal Dutch Shell plc 265
Sasol Limited 266
Shin-Etsu Chemical Company Limited 268
Solvay SA 270
SPI Pharma, see Associated British Foods
Stepan Company 271
Tate & Lyle plc 273
Tessenderlo Group NV 275
USG Corporation 276
Wacker Chemie AG 277
Other Companies Mentioned in Study 280


LIST OF TABLES

SECTION I -- EXECUTIVE SUMMARY
Summary Table 3
SECTION II -- MARKET ENVIRONMENT
1 Macroeconomic Indicators 9
2 Population & Households 13
3 National Health Expenditures 17
4 Chronic Conditions by Type 20
5 Acute Conditions by Type 21
6 Pharmaceutical Supply & Demand 22
7 Pharmaceutical Shipments by Therapeutic Class 24
8 Pharmaceutical Shipments by Dosage Formulation 26
9 Pharmaceutical Shipments by Distribution Classification 28
10 Pharmaceutical Shipments by Commercial Status 29
11 Excipient Market, 2003-2013 32
12 Pharmaceutical Excipient Pricing 34
SECTION III -- PRODUCTS
1 Pharmaceutical Excipient Demand by Product Group 41
2 Polymer Excipient Demand by Type & Application 44
3 Cellulose Excipient Demand by Type & Application 47
4 Microcrystalline Cellulose Excipient Demand by Application 50
5 Hydroxypropyl Methylcellulose Excipient Demand
by Application 53
6 Ethyl Cellulose Excipient Demand by Application 55
7 Methyl Cellulose Excipient Demand by Application 57
8 Carboxymethylcellulose Excipient Demand by Application 59
9 Croscarmellose Sodium Excipient Demand 61
10 Other Cellulose Excipient Demand by Application 64
11 Povidone Excipient Demand by Application 67
12 Starch Excipient Demand by Type & Application 69
13 Pregelatinized Starch Excipient Demand by Application 71
14 Sodium Starch Glycolate Excipient Demand 73
15 Other Starch Excipient Demand by Application 74
16 Polyethylene Glycol Excipient Demand by Application 80
17 Acrylic Polymer Excipient Demand by Application 84
18 Other Polymer Excipient Demand by Type & Application 85
19 Alcohol Excipient Demand by Type & Application 92
20 Propylene Glycol Excipient Demand by Application 94
21 Glycerin Excipient Demand by Application 96
22 Sorbitol Excipient Demand by Application 98
23 Other Alcohol Excipient Demand by Type & Application 99
24 Mineral Excipient Demand by Type & Application 106
25 Calcium Phosphate Excipient Demand 108
26 Calcium Carbonate Excipient Demand 110
27 Clay Excipient Demand by Application 112
28 Mineral Hydrocarbon Excipient Demand by Application 115
29 Silicon Dioxide Excipient Demand by Application 117
30 Titanium Dioxide Excipient Demand 118
31 Other Mineral Excipient Demand by Application 121
32 Gelatin Excipient Demand by Application 125
33 Sugar Excipient Demand by Type & Application 126
34 Lactose Excipient Demand by Application 129
35 Sucrose Excipient Demand by Application 131
36 Other Sugar Excipient Demand by Application 134
37 Other Pharmaceutical Excipient Demand by Type & Application 136
SECTION IV -- APPLICATIONS
1 Pharmaceutical Excipient Demand by Application 154
2 Filler & Diluent Excipient Demand by Type 157
3 Binder Excipient Demand by Type 160
4 Suspension & Viscosity Excipient Demand by Type 162
5 Coating Excipient Demand by Type 164
6 Solvent Excipient Demand by Type 166
7 Flavoring Agent Excipient Demand by Type 168
8 Capsule Excipient Demand by Type 171
9 Disintegrant Excipient Demand by Type 172
10 Colorant Excipient Demand by Type 174
11 Lubricant & Glidant Excipient Demand by Type 175
12 Preservative Excipient Demand by Type 177
13 Other Applications for Excipients by Type 178
1 US Excipient Sales by Company, 2013 180
2 Selected Acquisitions & Divestitures 187
3 Selected Cooperative Agreements 189


LIST OF CHARTS

SECTION III -- PRODUCTS
1 Excipient Demand by Product: Value & Volume, 2013 42
2 Polymer Excipient Demand: Value & Volume, 2013 45
SECTION IV -- APPLICATIONS
1 Pharmaceutical Excipient Demand by Application, 2013 155
SECTION V -- INDUSTRY STRUCTURE
1 US Excipient Market Share, 2013 182


Read the full report:
US Excipients Market

http://www.reportbuyer.com/pharma_healthcare/general_industry/us_excipients_market.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists discussed...
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists loo...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
"Loom is applying artificial intelligence and machine learning into the entire log analysis process, from start to finish and at the end you will get a human touch,” explained Sabo Taylor Diab, Vice President, Marketing at Loom Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, highlighted the current challenges of these transformative technologies and shared strategies for preparing your organization for these changes. This “view from the top” outlined the latest trends and developments i...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
"When we talk about cloud without compromise what we're talking about is that when people think about 'I need the flexibility of the cloud' - it's the ability to create applications and run them in a cloud environment that's far more flexible,” explained Matthew Finnie, CTO of Interoute, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
@DevOpsSummit at Cloud Expo taking place Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center, Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is ...
When growing capacity and power in the data center, the architectural trade-offs between server scale-up vs. scale-out continue to be debated. Both approaches are valid: scale-out adds multiple, smaller servers running in a distributed computing model, while scale-up adds fewer, more powerful servers that are capable of running larger workloads. It’s worth noting that there are additional, unique advantages that scale-up architectures offer. One big advantage is large memory and compute capacity...
The financial services market is one of the most data-driven industries in the world, yet it’s bogged down by legacy CPU technologies that simply can’t keep up with the task of querying and visualizing billions of records. In his session at 20th Cloud Expo, Karthik Lalithraj, a Principal Solutions Architect at Kinetica, discussed how the advent of advanced in-database analytics on the GPU makes it possible to run sophisticated data science workloads on the same database that is housing the rich...
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...
Artificial intelligence, machine learning, neural networks. We’re in the midst of a wave of excitement around AI such as hasn’t been seen for a few decades. But those previous periods of inflated expectations led to troughs of disappointment. Will this time be different? Most likely. Applications of AI such as predictive analytics are already decreasing costs and improving reliability of industrial machinery. Furthermore, the funding and research going into AI now comes from a wide range of com...